term welcoming considering long by Thank investing start shareholders, shareholders you, Assertio. and Matt. want I that in our new those are to
sheet priorities. develop business put success. a but my go for our XX legacy uncertainties. and new We in protect on CEO portfolio's My Assertio, a repositioned business extend to our and short diversify duration, create out cost ago, model reduce public path needed months improve flow cash I as generation, for call effectively profitability my the strategy business growth our ambitious, products more capital, Assertio legal INDOCIN, our improve laid sustainable to environment, necessary strategy add was first a mitigate and internal and opportunities changing that of very balance On our to compete forward to of a the and
to announcement recent we've key to ROLVEDON, say and this expected of in third that one achieving the by largely of asset, tactics just was Spectrum the of we set many do. their to the currently the be we will quarter, time closed Pharmaceuticals the The box and acquisition, completed proud the I'm we checked that acquisition of that everything have aim out sometime strategy.
heartfelt but a only thank worked of to you executive so employees goals. offer to in Assertio, the our want us team, have the not helping I of hard achieve to who all
a the where and of have critical and access close future, of with are business salesforce aligned market After the we'll business size. the today opposed the environment success of to as realities the pure acquisition, contracting to
soon addition, digital promotional complementary our our patients, into, In providing products value we and customers to have can platforms continue we'll add that shareholders. to further and in-person
net On date. has This to the our million million our is first $XX we've cash XX, had of a of term March and had the long impact profound time with balance strategy March on in execution most The maturity. XXXX position debt we been a sheet $XX.X since XXXX. positive of cash
XXXXs. over flipped years, maturing X.X% net $XX.X with little December debt debt, of more reduced and we've $XX and cash $XX two million acquire XX% we a net over XXXX, and assets an cash CEO by into of while when XXXX. million to For from In our cost all cash, of of comparison, $XX this, Paul positive in had to maturities and a the extended from in swing new two We achieved almost debt spending dramatic to took years, just even CFO, our of early million. patents I a three-and-a-half extending million
Assertio. first We a sales Zipsor a line. declining, of for the of quarter million XX% and $X strong exclusivity year grew was Cambia started the This Solumatrix the the hole with discontinuation both product and for prior quarter. loss net Instead due of product versus to
some extent and and more line, forecast, in including in products addition normal the Cambia. INDOCIN our outperformed Growth the top business to our expecting the made up those to seasonality but entered didn't Sympazan year materialize losses. our we of for than thought affect We the the demand see it of
and our Adjusted EBITDA platform investments also margin newest in behind putting X% Sympazan grew year-over-year, our effort making Otrexup. products, maintaining two at non-personal while marketing XX%, our and
of full result guidance expect sales performance now on $XXX change and quarter, to potential ASGE product X.X% adjusted for the both our EBITDA the a not net we're be million benefit adjusted of year of Those We net acquisition. to sales and this the X.X% product million. guidance increasing versus between our INDOCIN Spectrum to million, $XXX year. strong be EBITDA. numbers do And growth prior As to $XX the $XX representing include or full million
quarter non-commercial quarter, have improved volumes our product year, this on gross strategies XX%. sales executed where quarter. the with of increased from discounts. to first dramatically last flat INDOCIN's net eliminating XX% the by we are this growth channel net Yet In year we the the product in was prior fourth
We've the Society awareness also out guideline Endoscopy, campaigns ASGE. the Gastrointestinal about of recent changes from to roll or American begun
in if but email see well it's an early has first change too was which or The to was behavior. additional received, awareness will any the mid-April, campaign
as some to last education program effort, continuing which medical recently in July. weekend is also conduct advisory medical to that next launch is expected conference We sponsor attended an our this boards we plan important to
in revised a slightly outlook the increase still say in be recommendations it's demand increased will based a on in We've early there treatment of as ASGE. for our our but if definitively INDOCIN trends, guidance the result to change too from material
INDOCIN, procedures. and our for extension life We label efforts expansion prevention pancreatitis the cycle for primarily remain focused ERCP strategy on of our
the Dr. the from received early our Medical, working in our Franklin, biostatisticians We busy pre-IND of SVP meeting of Dr. we now need announced to some Howard appointment has This IND FDA feedback to D with and the request FDA. the believe Franklin the March, we will We meeting clarification delay before Type and IND. been submission. go with a the through the filing seek that incorporating back
sometime expected we guidance However, did spend half of revised included expect the have same of million timelines, last our million upon in based still $X year quarter. we approval the IND clinical still back as adjusted and the this to we EBITDA this year, $X our in later
expanded from with frequency our achieved In performing first non-personal prescription our Sympazan and demand. is quarter promotional with full well so platform. product, the we the reach quarterly far record
in high, as at beat XXXX TRx count the of previous monthly month in was the count, quarter Looking X.X%. new by X% TRx X.X% the and peak year previous third by beat Symphony we prior a Health, record of The the prior also year quarter beating XXXX measured and August by march by by X.X%. the XXXX
transition While a peak trend, new promotion. does high one not and before a comparison force month is this disruption make the sales non-personal important is the to since to
a shipments previous mix peak at ASP, this In the further quarter see we're above revenue X% to a come starting and addition, which higher were benefiting higher strengths, growth. shift are towards the ex-factory
I'm that, this of agree scratching just our to the drug's date, this surface we're at sure friends will Aquestive potential. developed drug who
our this more the refine could more getting market we Sympazan excited and potential. continue investors as improve think We'll plans the As about we learn and potential can to on what role about for more mean longer product. we we're its fill, give clarity that term
That released results of XX% is of job doing finally, And pending a quarter. for growth the sequential the million They turning the which clearly tremendous earlier in with to our today. to first quarter the Spectrum, acquisition $XX.X launch ROLVEDON. sales team reported
great run operating recording nearly under since that, that of only million is What's for approximately now expenses Spectrum. bring adjusted expect rate be EBITDA would is from an ROLVEDON legacy if revenue breakeven over platform, about that annual we to $XX at number Assertio's integrated
launch close of and ROLVEDON. meticulously increases two the Our into development of of priority a after combination The commercialize. number integration one the Assertio ensure pursue can these we is continued to planned opportunities successful effectively business Spectrum companies
access, of Spectrum in digital the this Assertio now market more with both manner. voice. and themselves promotional historical share than Combined, we're of both has one and And contrast Our and towards execution. business positioned been to have environment apart, moving contracting personal as stronger
and clinics like immunocompromised of algorithms. the protection that and offices believe our exclusivity. nature COVID is adapt NCCN oncology is patent communication importance oncology their communication and to receptive during size, were that almost assets to non-personal We populations an guidelines both treatment because to many the of The area and potential, growth objectives of that of patient fit setting non-personal in forced has
companies, size protected combination a supportive promotional opportunity patent late larger that oncology down of care purview. large of interesting market The contracting other's platforms, capabilities and pharma's many below are are There the door and our the optimizing M&A what to strengths in on is doubling products each the set. the stage opens two access and commercial and of
call over I'll Paul. that, to With turn the
